Press Room

2021 CPhI Worldwide

Tuesday, November 09, 2021 - 00:00
Thursday, November 11, 2021 - 00:00
Location: Milan, Italy
Booth Number: 2C30
CPhI Worldwide booth 2C30 The Specialist Integrated CDMO | Hovione

Join Hovione at CPhI Worldwide BOOTH # 2C30 and meet the team in whose attentive hands you can place your project.


Schedule a meeting at the Hovione's booth (#2C30) or online


Schedule a meeting button | Hovione





Faster time to market with a Specialized Integrated CDMO 

As a specialized integrated supplier Hovione offers services for drug substance, drug product intermediate and drug product for oral and inhaled solutions. Hovione offers all capabilities at the same site, providing a safer and simpler supply chain route towards commercial manufacturing, helping you bring new medicines to patients at an unprecedented speed.


We look forward to seeing you at CPhI Worldwide

to present the most reliable and innovative 
end-to-end solutions to help your project succeed








Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at  


Continuous Tableting and the Road to Global Adoption

Mar 04, 2024